Диссертация (1174281), страница 24
Текст из файла (страница 24)
162(1) – P. 27-34.157. Poli, D.The predictive ability of bleeding risk stratification models in very oldpatients on vitamin K antagonist treatment for venous thromboembolism: results of theprospective collaborative EPICA study/Poli D, Antonucci E, Testa S [et al.]//J ThrombHaemost. – 2013. – Vol. 11(6) – P. 1053-1058.158. Eichinger, S. Risk assessment of recurrence in patients with unprovoked deep veinthrombosis or pulmonary embolism: the Vienna prediction model/Eichinger S, Heinze G,Jandeck LM [et al.]//Circulation. – 2010. – Vol. 121 – P. 1630–1636.159. Tosetto, A. Predicting disease recurrence in patients with previous unprovokedvenous thromboembolism: a proposed prediction score (DASH)/Tosetto A, Iorio A,Marcucci M, [et al.]//J Thromb Haemost. – 2012.
– Vol. 10 – P. 1019–1025.160. Rodger, M.A. Identifying unprovoked thromboembolism patients at low risk forrecurrence who can discontinue anticoagulant therapy/Rodger MA, Kahn SR, Wells PS,[et al.]//CMAJ. – 2008. – Vol. 179 – P. 417–426.161. Fahrni, J. Assessing the risk of recurrent venous thromboembolism--a practicalapproach/ Fahrni J, Husmann M, Gretener SB [et al.]//Vasc Health Risk Manag. – 2015.– Vol.
11 – P. 451-459.163162. Louzada, M.L. Development of a clinical prediction rule for risk stratification ofrecurrent venous thromboembolism in patients with cancer-associated venousthromboembolism/Louzada ML, Carrier M, Lazo-Langner A [et al.]//Circulation. - 2012.– Vol. 126 – P. 448–454.163. den Exter, P.L. Validation of the Ottawa prognostic score for the prediction ofrecurrent venous thromboembolism in patients with cancer-associated thrombosis/denExter PL, Kooiman J, Huisman MV// J Thromb Haemost.
– 2013. – Vol. 11 – P. 998–1000.164. Kuijer, P.M. Prediction of the risk of bleeding during anticoagulant treatment forvenous thromboembolism/Kuijer PM, Hutten BA, Prins MH [et al.]//Arch Intern Med. 1999- Vol. 159 – P. 457–460.165. Kearon, C. Comparison of low-intensity warfarin therapy with conventionalintensitywarfarintherapyforlong-termpreventionofrecurrentvenousthromboembolism/Kearon C, Ginsberg JS, Kovacs MJ [et al.]//N Engl J Med. - 2003.Vol.
349 - P. 631–639.166. Ruiz-Gimenez, N. Predictive variables for major bleeding events in patientspresenting with documented acute venousthromboembolism. Findings from the RIETERegistry/Ruiz-Gimenez N, Suarez C, Gonzalez R [et al.] //Thromb Haemost. - 2008. –Vol. 100 – P. 26–31.167. Gage, B.F. Clinical classification schemes for predicting hemorrhage: results fromthe National Registry of Atrial Fibrillation (NRAF)/Gage BF, Yan Y, Milligan PE [etal.]//Am Heart J. - 2006.
– Vol. 151 – P. 713–719.168. Pisters, R. Major bleeding in patients with atrial fibrillation: the Euro HeartSurvey/Pisters R, Lane DA, Nieuwlaat R [et al.]// Chest. – 2010. - Vol. 138- P. 1093–1100.169. Fang, M.C. A new risk scheme to predict warfarin-associated hemorrhage: theATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study/Fang MC, Go AS,Chang Y [et al.]//J Am Coll Cardiol. – 2011.
– Vol. 58 – P. 395–401.164170. Beyth, R.J. Prospective evaluation of an index for predicting the risk of majorbleeding in outpatientstreated with warfarin/Beyth RJ, Quinn LM, Landefeld CS//Am JMed.- 1998. – Vol. 105 – P. 91–99.171. Scherz, N. Prospective, multicenter validation of prediction scores for majorbleeding in elderly patients with venous thromboembolism/Scherz N, Mean M, LimacherA [et al.]// J Thromb Haemost. – 2013. – Vol. 11 – P. 435–443.172. Donze, J. Scores to predict major bleeding risk during oral anticoagulation therapy:a prospective validation study/Donze J, Rodondi N, Waeber G [et al.] //Am J Med. - 2012.– Vol.
125 – P. 1095–1102.173. Riva, N. Poor predictive value of contemporary bleeding risk scores during longterm treatment of venous thromboembolism. A multicentre retrospective cohortstudy/Riva N, Bellesini M, Di Minno MN [et al.] //Thromb Haemost. – 2014. - Vol. 112– P. 511–521.174. Kooiman, J. The HAS-BLED score identifies patients with acute venousthromboembolism at high risk of major bleeding complications during the first six monthsof anticoagulant treatment/ Kooiman J, van Hagen N, Iglesias Del Sol A, [et al.]// PLoSONE.
– 2015. – Vol. 10 – eP. 0122520.175. Klok, F.A. Performance of five different bleeding-prediction scores in patients withacute pulmonary embolism/Klok, F.A., Niemann, C., Dellas, C [et al.]// J ThrombThrombolysis. – 2016. – Vol. 41 – P. 312.176. Dong, B. Thrombolytic treatment for pulmonary embolism/ Dong B, Jirong Y,Wang Q [et al.]//Cochrane Database Syst Rev – 2006. – Vol. 2 – P. CD004437.177. Kline, JA. Treatment of submassive pulmonary embolism with tenecteplase orplacebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebocontrolled randomized trial/Kline JA, Nordenholz KE, Courtney DM [et al.]//J ThrombHaemost.
– 2014. – Vol. 12(4) – P. 459-468.165178. Sharifi, M. Moderate Pulmonary Embolism Treated With Thrombolysis (from the“MOPETT” Trial)/ Sharifi M, Bay C, Skrocki L [et al.]//Am J Cardiol. – 2013. – Vol.111(2) – P. 273-277.179. Konstantinides, S. Heparin plus alteplase compared with heparin alone in patientswith submassive pulmonary embolism/Konstantinides S, Geibel A, Heusel G [et al.]// NEngl J Med. - 2002.
– Vol. 347(15) – P. 1143–1150.180. Meyer, G. Fibrinolysis for patients with intermediate-risk pulmonary embolism/Meyer G, Vicaut E, DanaysT, [et al.] //N Engl J Med. - 2014. – Vol. 370(15) – P. 1402–1411.181. Konstantinides, S. Association between thrombolytic treatment and the prognosisof hemodynamically stable patients with major pulmonary embolism: results of amulticenter registry/Konstantinides S, Geibel A, Olschewski M [et al.]//Circulation. 1997. – Vol. 96 – P.
882–888.182. Kasper, W. Management strategies and determinants of outcome in acute majorpulmonary embolism: results of a multicenter registry/Kasper W, Konstantinides S,Geibel A [et al.]//J Am Coll Cardiol. – 1997. – Vol. 30 – P. 1165–1171.183. Nakamura, M. Clinical characteristics of acute pulmonary thromboembolism inJapan: results of a multicenter registry in the Japanese Society of Pulmonary EmbolismResearch/Nakamura M, Fujioka H, Yamada N [et al.]//Clin Cardiol.
- 2001. – Vol. 2 –P. 132–138.184. Thabut, G. Thrombolytic therapy of pulmonary embolism: a meta-analysis/ThabutG, Thabut D, Myers R [et al.]//J Am Coll Cardiol. - 2002. – Vol. 40 – P. 1660–1667.185. Serra-Prat, M. Efficacy and safety of thrombolytic therapy in pulmonary embolism:meta-analysis of randomised controlled trials /Serra-Prat M, Jovell AJ, AymerichM.//Med Clin (Barc).
– 1999. – Vol. 112- P. 685–689.186. Agnelli, G. Thrombolysis vs heparin in the treatment of pulmonary embolism: aclinical outcome-basedmeta-analysis/Agnelli G, Becattini C, Kirschstein T//Arch InternMed. – 2002. – Vol. 162 – P. 2537–2541.166187. Kanter, D.S. Thrombolytic therapy for pulmonary embolism. Frequency ofintracranial hemorrhage and associated risk factors/Kanter DS, Mikkola KM, Patel SR,[et al.]//Chest. – 1997. – Vol. 111 – P. 1241–1245.188. Mikkola, K.M. Increasing age is a major risk factor for hemorrhagic complicationsafter pulmonary embolism thrombolysis/Mikkola KM, Patel SR, Parker JA [et al.]//AmHeart J.
– 1997. – Vol. 134 – P. 69–72.189. Kuo, W.T. Catheter- directed therapy for the treatment of massive pulmonaryembolism: systematic review and meta-analysis of modern techniques/Kuo WT, GouldMK, Louie JD [et al.]//J Vasc Interv Radiol. – 2009. – Vol. 20(11) – P. 1431–1440.190. Engelberger, R.P. Ultrasound-assisted thrombolysis for acute pulmonaryembolism: a systematic review/Engelberger RP, Kucher N.//Eur Heart J.- 2014. – Vol.35(12) – P. 758–764.191. Kucher, N. Randomized, controlled trial of ultrasound-assisted catheter-directedthrombolysis for acute intermediate-risk pulmonary embolism/Kucher N, Boekstegers P,Mu¨ller OJ [et al.]//Circulation. – 2014. – Vol.
129(4) – P. 479–486.192. Ottero, R. Haemodynamically unstable pulmonary embolism in the RIETERegistry: systolic blood pressure or shock index?/Otero R, Trujillo-Santos J, Cayuela A[et al.]// Eur Respir J. – 2007. – Vol. 30 – P. 1111–1116.193. Borg, G.A. Psychophysical bases of perceived exertion/Borg GA//Med Sci SportsExerc. – 1982 – Vol.
14 – P. 377–381.Laporte, S. Clinical Predictors for Fatal PulmonaryEmbolism in 15 520 Patients With Venous Thromboembolism Findings From theRegistroInformatizadodelaEnfermedadTromboEmbolicavenosa(RIETE)[Электронный ресурс]/ S. Laporte, P. Mismetti, H. Décousus, [et al.]//Registry.- Режим доступа: http://dx.doi.org/10.1161/CIRCULATIONAHA.107.726232195. Nieto, J.A. Fatal bleeding in patients receiving anticoagulant therapy for venousthromboembolism: findings from the RIETE registry/Nieto JA, Solano R, Ruiz-Ribó MD,[et al.] //J Thromb Haemost. – 2010.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
